ANI Pharmaceuticals Turns To Q3 Profit, Raises Full-year Outlook

Nov 8, 2023 · ANI Pharmaceuticals Turns To Q3 Profit, Raises Full-year Outlook November 08, 2023 — 07:27 am EST. ... (RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) Wednesday …

13%
OFF

ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: …

2 weeks from now

Nov 9, 2024 · ANI Pharmaceuticals Inc (ANIP) reports a 13% revenue increase and raises full-year guidance, driven by Cortrophin Gel demand and strategic acquisitions.

yahoo.com

$9.53
OFF

ANI Pharmaceuticals Turns To Q3 Profit, Raises Full-year Outlook ...

2 weeks from now

Nov 8, 2023 · (RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) Wednesday reported profit of $9.53 million or $0.45 per share for the third quarter, compared with lo...

businessinsider.com

$24.57
OFF

ANI Pharma Boosts FY24 Outlook As Q3 Results Top Estimates

2 weeks from now

Nov 8, 2024 · For the third quarter, the company reported a net loss available to common shareholders of $24.57 million or $1.27 per share, compared to net income of $9.53 million or …

nasdaq.com

$594
OFF

ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial …

2 weeks from now

Nov 8, 2024 · Revised Full Year 2024 Guidance : Prior Full Year 2024 Guidance : 2023 Actual : Growth : Net Revenue (Total Company) $594 million - $602 million : $540 million - $560 million …

businessinsider.com

$1.34
OFF

ANI Pharma Boosts FY24 Outlook As Q3 Results Top Estimates

2 weeks from now

Nov 8, 2024 · Excluding items, adjusted earnings for the quarter was $1.34 per share, compared to $1.27 per share in the year-ago quarter. Net revenues for the quarter grew to $148.33 …

businessinsider.com

13%
OFF

ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights:

2 weeks from now

Nov 9, 2024 · Total Revenue: $148.3 million, an increase of 13% over Q3 2023.Adjusted Non-GAAP EBITDA: $35.1 million.Adjusted Non-GAAP EPS: $1.34.Cortrophin Gel Revenue: $52 …

gurufocus.com

$148
OFF

ANI Pharmaceuticals’ Record Growth And Strategic Acquisition

2 weeks from now

Nov 9, 2024 · The company also raised its full-year 2024 guidance, reflecting strong business momentum.Key highlights from ANI’s report include record quarterly net revenues of $148.3 …

nasdaq.com

3%
OFF

ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial …

2 weeks from now

Nov 8, 2023 · ANI Pharmaceuticals, Inc. Third Quarter 2023 Financial Results-- Record quarterly net revenues of $131.8 million, representing year-over-year growth of 57.3%; net income …

yahoo.com

$594
OFF

Earnings Call: ANI Pharmaceuticals Q3 Results - Revenue Up, Raises ...

2 weeks from now

Nov 11, 2024 · Full year 2024 net revenues of $594 million to $602 million, up from our prior guidance of $540 million to $560 million, representing year-over-year growth of approximately …

investing.com

0%
OFF

ANI Pharmaceuticals Affirms 2024 Guidance And Provides …

2 weeks from now

3 days ago · ANI Pharmaceuticals expects strong 2024 revenues, with preliminary 2025 guidance indicating growth i. ... UBS GROUP AG added 254,514 shares (+796.0%) to their portfolio in …

quiverquant.com

94%
OFF

ANI Pharmaceuticals (ANIP) Q3 Earnings And Revenues Surpass …

2 weeks from now

Nov 8, 2024 · ANI (ANIP) delivered earnings and revenue surprises of 22.94% and 3.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies …

zacks.com

$1.27
OFF

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2023 Earnings Call …

2 weeks from now

Nov 9, 2023 · ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.27, expectations were $0.76. Operator: Good day, everyone, and welcome to the ANI …

yahoo.com

$1.34
OFF

ANI Pharmaceuticals Reports Q3 Adjusted EPS $1.34, Consensus …

2 weeks from now

Nov 8, 2024 · ANI Pharmaceuticals reports Q3 adjusted EPS $1.34, consensus $1.09 November 08, 2024 — 06:55 am EST Written by TheFly for TipRanks ->

nasdaq.com

5%
OFF

ANI Pharmaceuticals Hits Record Q3 Revenue, Cortrophin Sales …

2 weeks from now

Nov 8, 2024 · ANI Pharmaceuticals (ANIP) reported record Q3 2024 results with net revenues of $148.3 million, up 12.5% year-over-year.The company's lead product, Cortrophin Gel, …

stocktitan.net

25%
OFF

ANI Pharmaceuticals Projects Strong 25% Growth For 2025, …

2 weeks from now

3 days ago · ANI Pharmaceuticals (ANIP) has announced preliminary financial results for Q4 and full-year 2024, along with its 2025 outlook. Based on unaudited results, the company expects …

stocktitan.net

$590.31
OFF

ANI Pharmaceuticals Inc ( NASDAQ:ANIP ) Estimates Trends

2 weeks from now

Nov 7, 2024 · The full year 2024's revenue is expected to be $590.31 million and the earnings are expected to be $0.99 per share. ... ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Report …

yahoo.com

$1.34
OFF

ANI Pharmaceuticals (ANIP) Q3 Earnings And Revenues Surpass

2 weeks from now

Nov 8, 2024 · ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of …

nasdaq.com

$59
OFF

ANI Pharmaceuticals Provides Preliminary Fourth Quarter And 2024 ...

2 weeks from now

3 days ago · Preliminary Fourth Quarter and Full Year 2024 Financial Results. Based on preliminary, unaudited results, ANI expects Purified Cortrophin Gel net revenues of $59.2 …

yahoo.com

24%
OFF

ANI Pharmaceuticals Affirms 2024 Guidance And Provides

2 weeks from now

3 days ago · Preliminary Full Year 2025 Outlook. For full year 2025, ANI expects total net revenues of between $739 million and $759 million, representing growth of 24% to 27% as …

nasdaq.com

FAQs about ANI Pharmaceuticals Turns To Q3 Profit, Raises Full-year Outlook Coupon?

How did ANI Pharmaceuticals perform in the third quarter?

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) Wednesday reported profit of $9.53 million or $0.45 per share for the third quarter, compared with loss of $9.01 million or $0.55 per share in the same quarter a year ago, driven by growth in product sales. The company also raised its full-year outlook above the Street view. ...

Did ANI Pharmaceuticals raise earnings guidance for the third quarter 2024?

(RTTNews) - While reporting financial results for the third quarter on Friday, biopharmaceutical company ANI Pharmaceuticals, Inc. (ANIP) raised its adjusted earnings and net revenue guidance for the full-year 2024, which now includes the anticipated results of Alimera from September 16, 2024. ...

How much revenue does Ani expect from the acquisition?

The acquisition contributed $3.9 million of revenues to ANI for the last two weeks of the quarter, and the Company expects revenue between $30.0 million and $32.0 million for the year (for the period of September 16, 2024 through December 31, 2024). New Capital Structure ...

Does ANI Pharmaceuticals have a financial outlook for 2025?

BAUDETTE, Minn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today affirmed its prior net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS guidance for 2024 and provided its preliminary financial outlook for 2025. ...

How did ANI Pharmaceuticals Inc's earnings compare to analysts' expectations?

In the previous quarter of 2024-06-30, ANI Pharmaceuticals Inc's (NASDAQ:ANIP) actual revenue was $138.04 million, which beat analysts' revenue expectations of $129.054 million by 6.96%. ANI Pharmaceuticals Inc's (NASDAQ:ANIP) actual earnings were -$0.14 per share, which missed analysts' earnings expectations of $0.077 per share by -281.82%. ...

How did Ani perform in the third quarter of 2024?

Third Quarter and Recent Business Highlights: Rare Disease Segment Revenues for ANI’s lead asset, Cortrophin Gel, totaled $52.6 million for the third quarter of 2024, an increase of 76.8% over the same period in 2023, driven by increased volume from both overall ACTH market growth and share growth. ...